2023
Proteasome Inhibitors Interact Synergistically with BCL2, Histone Deacetylase, BET, and Jak Inhibitors against Cutaneous T-Cell Lymphoma Cells
Xu S, Ren J, Lewis J, Carlson K, Girardi M. Proteasome Inhibitors Interact Synergistically with BCL2, Histone Deacetylase, BET, and Jak Inhibitors against Cutaneous T-Cell Lymphoma Cells. Journal Of Investigative Dermatology 2023, 143: 1322-1325.e3. PMID: 36642402, DOI: 10.1016/j.jid.2022.12.017.Peer-Reviewed Original Research
2017
Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients
Cyrenne BM, Lewis JM, Weed JG, Carlson KR, Mirza FN, Foss FM, Girardi M. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients. Blood 2017, 130: 2073-2083. PMID: 28972015, PMCID: PMC5680613, DOI: 10.1182/blood-2017-06-792150.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaB-cell lymphoma 2Advanced cutaneous T-cell lymphomaCutaneous T-cell lymphoma patientsHDAC inhibitionT-cell lymphoma patientsNovel BCL2 inhibitorPeripheral blood involvementAvailable systemic therapiesWorse clinical outcomesTreatment of patientsNon-Hodgkin lymphomaT-cell lymphomaCTCL cell linesPotential therapeutic targetHistone deacetylase inhibitionQuality of lifeHistone deacetylase inhibitorsBlood involvementSystemic therapyClinical outcomesTumor burdenLymphoma patientsCombination therapyBCL2 inhibitors
2008
FDG-PET/CT for the Evaluation of Response to Therapy of Cutaneous T-cell Lymphoma to Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in a Phase II Trial
Kuo PH, Carlson KR, Christensen I, Girardi M, Heald PW. FDG-PET/CT for the Evaluation of Response to Therapy of Cutaneous T-cell Lymphoma to Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in a Phase II Trial. Molecular Imaging And Biology 2008, 10: 306-314. PMID: 18665425, DOI: 10.1007/s11307-008-0161-4.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaFDG PET/CTPhase II trialParticular positron emission tomographyT-cell lymphomaII trialNodal diseaseInitial PET/CT scanPET/CT scansEarly clinical trialsEvaluation of responseHistone deacetylase inhibitorsAlters gene transcriptionPositron emission tomographyFDG uptakeCutaneous lesionsFDG-PETPrognostic valueFuture trialsClinical trialsConclusionFurther studiesCell lymphomaCT scanDeacetylase inhibitorsHDAC inhibitors